Marshall Wace
RPRX icon

Marshall Wace’s Royalty Pharma RPRX Stock Holding History

Marshall Wace’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
2,450,669
+329,977
+16% +$17.2M 0.11% 143
2026
Q1 		$102M Buy
2,120,692
+1,723,954
+435% +$75.5M 0.1% 165
2025
Q4 		$15.3M Sell
396,738
-1,086,938
-73% -$41.4M 0.01% 727
2025
Q3 		$52.3M Buy
+1,483,676
New +$53.7M 0.05% 307
2024
Q3 		– Sell
-945,840
Closed -$24.9M – 2896
2024
Q2 		$24.9M Sell
945,840
-510,060
-35% -$14.1M 0.03% 433
2024
Q1 		$44.2M Buy
1,455,900
+15,857
+1% +$467K 0.07% 282
2023
Q4 		$40.5M Buy
1,440,043
+1,275,233
+774% +$35M 0.07% 287
2023
Q3 		$4.47M Sell
164,810
-1,641,811
-91% -$48.8M 0.01% 915
2023
Q2 		$55.5M Buy
1,806,621
+1,134,091
+169% +$38.4M 0.11% 196
2023
Q1 		$24.2M Buy
+672,530
New +$24.9M 0.05% 401
2022
Q4 		– Sell
-432,250
Closed -$17.4M – 3351
2022
Q3 		$17.4M Buy
+432,250
New +$18.5M 0.04% 527
2022
Q2 		– Sell
-74,655
Closed -$2.91M – 3785
2022
Q1 		$2.91M Sell
74,655
-116,191
-61% -$4.56M 0.01% 1811
2021
Q4 		$7.61M Sell
190,846
-1,011,134
-84% -$39.3M 0.01% 1065
2021
Q3 		$43.4M Buy
+1,201,980
New +$46.7M 0.18% 99
2020
Q4 		– Sell
-29,255
Closed -$1.23M – 2131
2020
Q3 		$1.23M Buy
+29,255
New +$1.26M 0.01% 945

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's RPRX Position: Q2 2026 in Review

Marshall Wace increased its Royalty Pharma (RPRX) stake by 16% in Q2 2026, buying an estimated $17.2M and bringing the position to 2,450,669 shares worth $137M. The position accounts for 0.11% of the portfolio, ranked #143.

Marshall Wace first reported a position in RPRX in Q3 2020 and has held it in 15 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Marshall Wace held 2,450,669 shares of Royalty Pharma worth $137M as of Q2 2026.
  • Marshall Wace bought 329,977 Royalty Pharma shares in Q2 2026, an estimated $17.2M.
  • Royalty Pharma made up 0.11% of Marshall Wace's portfolio in Q2 2026, its #143 holding.
  • Marshall Wace first reported a position in Royalty Pharma in Q3 2020 and has held it in 15 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.